Skip to content

Depression research published in 2026

Page 33 of 37: studies 641 to 660 of 725, newest first. Back to the depression overview

Studies

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Translational Psychiatry January 23, 2026 Stevan Nikolin, Clara Massaneda-Tuneu, Louise Brettell et al. 1 citation

Comparing treatments for severe and medication-resistant depression is essential for guiding clinical decision-making. In this meta-analysis, we investigate the efficacy of electroconvulsive therapy (ECT) compared to ketamine for the treatment of major depressive disorder (MDD) and address the discrepant results of prior meta-analyses. We systematically searched PubMED (MEDLINE), Embase, and...

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

Journal of Neuroinflammation January 22, 2026 Ang Liu, Xiao-Qi Zhang, Jia-Xin Guo et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors,...

Progress, potential and pitfalls of ketamine as a treatment for depression

Expert Opinion on Pharmacotherapy January 22, 2026 Diana Orsini, Sara Di Luch, Gabrielle F. M. Lovell et al.

Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clinical trials and real-world effectiveness studies supporting antidepressant effects. Larger studies have provided reassuring data supporting an adequate safety profile, including safety data with long-term treatment. Alternative routes of...

Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment.

Neuroscience January 22, 2026 Guilherme Lodetti, Gislaine Zilli Réus, Eduardo Pacheco Rico

Pharmacotherapy for MDD is commonly prescribed to patients, yet fewer than half achieve remission. Moreover, many patients exhibit intolerant responses to pharmacological treatment, highlighting the need to explore new forms of therapy. The present work provides a narrative review of classic psychedelics as an alternative to MDD treatment. In addition, mechanisms by which psychedelics exert...

Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.

Indian Journal of Psychological Medicine January 22, 2026 Zaid Ahmad Wani, Rajnish Raj, Shabir Ahmad Dar et al.

Depression is a significant global health issue, often accompanied by suicidality, which requires urgent and effective interventions. Oral ketamine is emerging as a potential rapid-acting treatment, but data on its efficacy and tolerability remain limited, particularly in the Indian context. Thus, this retrospective study was conducted to assess the response to oral ketamine in patients with...

DOI: 10.1177/02537176251415001 (opens in new tab) Full text (opens in new tab) Depression Oral ketamine Rapid-acting antidepressant Sociocultural factors +1

The Effects of a Brief Mindful Walking Intervention on Mindfulness, Depression, Anxiety and Stress in Novice Meditators

Appalachian State University January 21, 2026

Research suggests that regular mindfulness meditation practice leads to a variety of beneficial outcomes, including improved mood and well-being. Although mindfulness meditation has traditionally been practiced in various forms, the vast majority of the psychological literature on the topic has examined the effects of seated mindfulness exercises. Mindful walking has been practiced for...

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.

The Journal of Clinical Psychiatry January 21, 2026 Matheus G Marques, Aysegul Özerdem, Simon Kung et al. 1 citation

Objective: Treatment-resistant depression (TRD) affects one-third of patients with major depressive disorder, leading to increased morbidity, health care costs, and suicide risk. TRD lacks a standardized definition, complicating treatment selection. Current guidelines often group treatments broadly without clear prioritization, and evidence gaps persist, particularly regarding newer...

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms

Neuropharmacology January 21, 2026 Ana Domi, Erika Lucente, Davide Cadeddu et al. 1 citation

Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neurotransmission in the prefrontal cortex...

DOI: 10.1016/j.neuropharm.2026.110854 (opens in new tab) Serotonergic Infralimbic cortex Neurotransmission Glutamatergic +5

[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University January 20, 2026 Ke Xia, Tianming Gao

Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed onset and insufficient efficacy. Classic psychedelics, most notably psilocybin, have recently emerged as promising candidates for treatment of depression and demonstrated rapid, robust, and sustained antidepressant effects in controlled clinical...

The Effect of Meditation on Depression and Psychological Well-being Among Active Smokers.

Annals of Neurosciences January 19, 2026 Gurpreet Verma, Vijendra Nath Pathak, Prabhjyot Kour et al.

Depression and active smoking are very common situations among the population, which also reduces the positive mental well-being of a person. Smoking is a global issue, and depression and low mental well-being interfere with the daily lives of individuals. This study aimed to investigate the effect of meditation on an active smoker in terms of depression and psychological well-being (PWB) as...

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Journal of Affective Disorders January 19, 2026 Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.

Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

Psychedelic Medicine January 18, 2026 Anthony L. Back, Bonnie A. Mcgregor, Leslie Lazar Thorn et al. 1 citation

Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility criteria included metastatic cancer, moderate-to-severe symptoms of anxiety or...

Evaluating the Impact of Sahaja Yoga Meditation on Anxiety and Depression Using Machine Learning Models

International Journal of Latest Technology in Engineering Management & Applied Science January 15, 2026

Anxiety and depression affect people, around the world. The need, for effective, accessible non‑drug treatments is clear. Sahaja Yoga meditation is a practice that can lower stress and boost emotional health. The study examines how Sahaja Yoga meditation changes anxiety and depression using machine learning models. The researchers collected a dataset from participants who practiced Sahaja Yoga...

Psilocibina como ferramenta terapêutica em transtornos depressivos em adultos: uma revisão sistemática das evidências e impactos

Brazilian Journal of Implantology and Health Sciences January 15, 2026 Bianca Gasparotto da Silva, Giovana Labegaline Araújo, Bruna Rafaela Prestes et al.

Os transtornos depressivos representam uma das principais causas de incapacidade global, afetando de forma significativa o funcionamento emocional, social e ocupacional dos indivíduos. Apesar da ampla disponibilidade de antidepressivos convencionais, muitos pacientes apresentam resposta insuficiente ou efeitos adversos limitantes, especialmente aqueles com depressão resistente ao tratamento...

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

January 15, 2026 Benjamin Kelmendi, Thomas G. Adams, Terence H. W. Ching et al. preprint

Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD.Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with treatment-resistant OCD to receive a...

Simulating Synaptic Pruning and Ketamine-Like Recovery in Depression: Insights from Consolidation Duration and Iterative Regimens on Resilience and Relapse

Zenodo (CERN European Organization for Nuclear Research) January 14, 2026 Ngo Cheung 1 citation preprint

Background: Major depressive disorder (MDD) is increasingly framed as a failure of neuroplasticity. Excessive synaptic pruning in adolescence can leave circuits fragile; later stress then unmasks the weakness, whereas ketamine and related compounds can quickly rebuild critical synapses. Clinical data show that a single treatment often gives short relief, while repeated courses reduce relapse....

DOI: 10.5281/zenodo.18246390 (opens in new tab) Consolidation business Robustness evolution Time point Stimulus psychology +5